Eli Lilly and 10Q 2009 Q1 Quarterly report | LLY Filing

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	8th grade Avg

New words: accrual, accumulated, ACS, adjunctive, Advisory, aggressive, agricultural, antiplatelet, API, apportioned, approach, assessing, assessment, assist, atherothrombotic, awaiting, BI, biologic, biosimilar, BMS, Boehringer, Brazil, budget, bulk, capacity, carcinoma, Cardiovascular, Chase, classify, classifying, Cobalt, concentration, constructing, consumption, contract, convert, converted, correlation, Cosmetic, curve, decided, default, delinquency, dementia, denominated, detailing, directed, distribution, documented, doubt, downturn, duloxetine, duration, earned, economy, Efient, elderly, eligible, eliminate, eliminated, equally, Erbitux, euro, exceeding, exenatide, exposed, floating, flow, fluctuating, fluoxetine, forward, found, France, FSP, geographic, glycemic, greater, guilty, head, heightened, HHS, Humulog, Impax, indexed, Ingelheim, ingredient, Inspector, instrument, Interactive, interchange, interim, inventor, issuable, issuer, Japanese, JPMorgan, KGaA, largest, legislature, level, life, loan, long, Lupin, macroeconomic, Madrid, manner, maximum, Merck, metformin, misdemeanor, mitigated, neck, negative, nonperformance, objective, occurrence, OIG, option, orderly, overturned, owe, pathway, PCI, pled, policy, population, post, posted, pound, predetermined, prime, procedure, produce, promissory, pronounced, public, qualify, quickly, quoted, raloxifene, real, reconfirm, reconsider, recovery, reform, Regulation, Renal, repaid, repay, repayable, reply, rest, retroactively, reversed, sBLA, SCCHN, security, sensitive, shorter, show, situation, Sixteen, slowdown, source, spending, Squibb, strive, submission, sulfonylurea, supermajority, supply, supplying, swap, Symbyax, taxation, thiazolidinediene, threshold, tightened, topic, trade, tradename, traditionally, TRD, Trustee, tumor, unaffected, uncertain, undergoing, underinsured, unemployment, uninsured, Union, unique, Vanderbilt, variability, vary, varying, vintage, virtue, Web, Wockhardt, write, Xigrisand, Xigris®and, yen, yield

Removed: added, adjust, advance, affecting, allegedly, America, appealing, applying, approvable, Arxxant, average, awarded, Axid, barring, Boston, broad, broadly, calculated, capitalized, cisplatin, clearance, companion, comply, comprising, conceded, contention, contest, coordinating, country, delivered, deterioration, discontinued, EMEA, enforceability, enhance, established, Europe, excessive, expired, expiry, FIN, Florida, Forsteo, framework, Glenmark, glucocorticoid, grand, grew, growing, histology, impermissibly, infringe, inquiry, investigative, issuance, issuing, Ivy, Jersey, lung, manager, measuring, medication, monotherapy, Mylan, nonmonetary, nonrefundable, North, observed, operational, OSI, participating, patentable, permanent, predominantly, principle, prospectively, realize, rebate, recent, reexamination, rejection, relate, rendered, rose, sedation, slower, statutory, stay, sustained, syndrome, Synthon, systemic, understand, unpatentable, USPTO, venture, voluntary


	Three Months Ended
	March 31,
	2009		2008

BASIC
Net income	$	1,313.1	$	1,064.3

Average number of common shares outstanding		1,094.2		1,091.5
Contingently issuable shares		3.0		2.4

Adjusted average shares		1,097.2		1,093.9

Basic earnings per share	$	1.20	$	.97

DILUTED
Net income	$	1,313.1	$	1,064.3

Average number of common shares outstanding		1,094.2		1,091.5
Incremental shares — stock options and contingently issuable shares		3.1		2.6

Adjusted average shares		1,097.3		1,094.1

Diluted earnings per share	$	1.20	$	.97


EXHIBIT 11.		STATEMENT RE: COMPUTATION OF EARNINGS PER SHARE

Eli Lilly and (LLY) 10-Q2009 Q1 Quarterly report

Content analysis